10.31.24 -- Driving Therapeutic Innovation With Bioconjugates

Bioconjugation is now a cornerstone technology – with applications in biomaterials for medical use and biosensors for diagnostics purposes. Harness the power of bioconjugation to revolutionize targeted therapies, enhance drug efficacy, and reduce side effects, paving the way for more precise and effective treatments across a range of diseases.

Comprised of therapeutic agents attached to biological targeting molecules, bioconjugates give a drug unprecedented targeting capability. Here, we examine how to accelerate the development of complex bioconjugates to unlock new possibilities for targeted therapies and advance the next generation of precision medicine.

Antibody-Drug Conjugates (ADCs) have the potential to reshape cancer treatment, but realizing their full therapeutic promise requires addressing critical challenges in drug design, delivery, and safety. However, the expertise gained from ADC development is not confined to cancer therapies alone. The potential of applying ADC techniques to antibody-oligo conjugates (AOCs, to interfere with mRNA and, thus, protein production, offering more treatments options to treat a higher volume diseases.

Optimizing and scaling up a bioconjugate can present many challenges. This on-demand webinar addresses these hurdles head-on, equipping you with the critical design and process development steps to ensure the success of your next-generation bioconjugate. Discover innovative techniques for incorporating engineered cysteines into ADC manufacturing, streamlining the production process. Additionally, we'll explore cutting-edge manufacturing strategies for bioconjugates containing novel payloads, such as radioimmunoconjugates and oligonucleotide conjugates.